114 related articles for article (PubMed ID: 28468742)
1. Caelyx-induced unilateral erythrodysesthaesia secondary to venous thromboembolism.
Merika EE; Gore M; Fearfield LA
Eur J Dermatol; 2017 Jun; 27(3):321-322. PubMed ID: 28468742
[No Abstract] [Full Text] [Related]
2. Hand-foot syndrome related to liposomal doxorubicin.
Swenson KK; Bell EM
Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920
[No Abstract] [Full Text] [Related]
3. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
Mrochen-Domin I; Nowara E; Kaleta B
Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
5. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
Zvaríková M
Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
[No Abstract] [Full Text] [Related]
6. [Absence of cutaneous complications following extravasation of pegylated liposomal doxorubicin].
Capitain O; Lortholary A
Presse Med; 2003 Jun; 32(23):1077. PubMed ID: 12910162
[No Abstract] [Full Text] [Related]
7. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
8. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
[TBL] [Abstract][Full Text] [Related]
9. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos R; Cathomas R
Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
[No Abstract] [Full Text] [Related]
10. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
[TBL] [Abstract][Full Text] [Related]
13. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
[TBL] [Abstract][Full Text] [Related]
14. Hand-foot syndrome.
Pike K
Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
[No Abstract] [Full Text] [Related]
15. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and soles.
Ziemer M; Goetze S; Kaatz M; Elsner P
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S44-6. PubMed ID: 18191705
[No Abstract] [Full Text] [Related]
[Next] [New Search]